“A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors”
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
Drug - BMS-986226
specified dose on specified days
Biological - Nivolumab
specified dose on specified days
Biological - Ipilimumab
specified dose on specified days
Biological - Tetanus Vaccine
specified dose on specified days
A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
NCT03251924
Xe0zXb